Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management cut its Regeneron stake by 84.9% in the third quarter, selling 208,046 shares and retaining 36,881 shares valued at approximately $28 million.
• Institutional investors still hold a significant position in Regeneron, with hedge funds and other institutions owning 83.31% of the stock; several major firms initiated or expanded stakes during the second quarter.
• Analyst sentiment remains favorable, with Regeneron carrying a consensus “Moderate Buy” rating and an average price target of $845.21. The company also reported better-than-expected quarterly results, including $4.29 billion in revenue and $14.29 in earnings per share.

Assenagon Asset Management S.A. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 84.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,881 shares of the biopharmaceutical company's stock after selling 208,046 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Regeneron Pharmaceuticals were worth $27,966,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $5,682,636,000. Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $473,872,000. Bank of New York Mellon Corp acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $472,950,000. Deutsche Bank AG purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $323,249,000. Finally, Man Group plc purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $272,460,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research report on Monday, August 3rd. Evercore raised their target price on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an "outperform" rating in a research note on Wednesday, September 9th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $845.21.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly performance supported the bullish case. Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above analyst expectations. Earnings per share of $14.29 also exceeded the $10.16 consensus estimate, reinforcing confidence in the company’s earnings momentum. Regeneron earnings and investment narrative
• Positive Sentiment: Positive 84-week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva indicated a sustained reduction in new heterotopic bone lesions and disease flare-ups, with a generally consistent safety profile. The results could strengthen confidence in the treatment’s commercial opportunity. Regeneron OPTIMA trial results
• Positive Sentiment: UBS upgraded REGN to Buy and raised its price target to $978 from $660, citing greater long-term potential for Dupixent and arguing that the market may be undervaluing the business. UBS Regeneron upgrade
• Positive Sentiment: Libtayo received a positive recommendation from the European Medicines Agency’s CHMP for a dosing regimen that could reduce administration frequency from every three weeks to every six weeks after the first 12 weeks, potentially improving convenience and market appeal. Final EU approval is still required. Libtayo CHMP recommendation
• Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it may contribute modestly to near-term caution. Regeneron insider sale filing

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 8,093 shares of company stock valued at $6,506,845. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $790.74 on Monday. The company has a market capitalization of $81.41 billion, a price-to-earnings ratio of 19.54, a price-to-earnings-growth ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a one year low of $566.11 and a one year high of $859.34. The stock has a 50-day simple moving average of $791.72 and a 200 day simple moving average of $721.59. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company earned $12.81 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.